Company Filing History:
1 out of 1,778 
1 out of 1 Years Active: 2012
Title: The Innovations of Peter Reumert Wagtmann
Introduction
Peter Reumert Wagtmann is a notable inventor based in Rungsted Kyst, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of agents that enhance natural killer (NK) cell activity. His work focuses on improving therapeutic strategies for various diseases.
Latest Patents
Wagtmann holds a patent for "KIR-binding agents and methods of use thereof." This invention relates to agents and methods capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signaling without diminishing the binding of KIR to HLA-C. The patent describes how transduction of negative signaling via KIR can involve a conformational reorientation of KIR molecules, leading to accelerated clustering and enhanced cytotoxicity. The methods and agents, including monoclonal antibodies, aim to reduce KIR-mediated inhibition of NK cell cytotoxicity while preserving HLA-binding.
Career Highlights
Throughout his career, Wagtmann has worked with prominent companies in the biotechnology sector, including Novo Nordisk A/S and Inmate Pharma S.A.S. His experience in these organizations has contributed to his expertise in developing innovative solutions in the field.
Collaborations
Wagtmann has collaborated with several professionals in his field, including Søren Berg Padkær and Pieter Spee. These collaborations have further enriched his research and development efforts.
Conclusion
Peter Reumert Wagtmann is a distinguished inventor whose work in KIR-binding agents has the potential to significantly impact therapeutic approaches in immunology. His contributions to biotechnology continue to pave the way for advancements in medical treatments.